Related Experiment Video
Updated: May 29, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
A comprehensive pharmacological survey across heterogeneous patient-derived glioblastoma stem cell models
Richard J R Elliott1, Peter W K Nagle1, Muhammad Furqan1
1Cancer Research UK Scotland Centre (Edinburgh), Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, UK.
Abstract:
The lack of advancement in the treatment of glioblastoma (GBM) over the past two decades calls for more innovation to address the inter- and intra-patient heterogeneity confounding modern target-directed drug discovery strategies. In this study, we incorporate a panel of patient-derived GBM stem cell lines into an automated and unbiased "cell painting" assay to quantify multiple GBM stem cell phenotypes. By screening several compound libraries, followed by dose-response validation of hit compounds, we present a comprehensive survey of distinct pharmacological classes and druggable targets upon multiple GBM stem cell phenotypes. We further characterize two validated target classes, histone deacetylase and cyclin dependent kinase inhibitors. We demonstrate that unbiased Cell Painting phenotypic screening is a productive approach to identifying new targets, drug classes and future drug combinations that address the heterogeneity of GBM. We provide all GBM cell painting data for each compound perturbation for the research community to explore further.
Insights
This study used Cell Painting to screen compounds against glioblastoma (GBM) stem cells, identifying new drug targets and classes. This approach addresses GBM
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Glioblastoma (GBM) treatment has seen limited progress due to significant patient heterogeneity.
- Target-directed drug discovery is challenged by inter- and intra-patient variability in GBM.
Purpose of the Study:
- To develop an innovative approach for identifying novel therapeutic targets and drug classes for glioblastoma.
- To leverage phenotypic screening to overcome challenges posed by GBM heterogeneity.
Main Methods:
- Utilized patient-derived GBM stem cell lines.
- Employed an automated and unbiased "cell painting" assay to quantify cellular phenotypes.
- Screened compound libraries and performed dose-response validation of hit compounds.
Main Results:
- Identified distinct pharmacological classes and druggable targets across multiple GBM stem cell phenotypes.
- Validated histone deacetylase and cyclin-dependent kinase inhibitors as promising target classes.
- Demonstrated the efficacy of Cell Painting for identifying novel therapeutic strategies.
Conclusions:
- Unbiased Cell Painting phenotypic screening is a powerful strategy for discovering new drug targets and classes for glioblastoma.
- This approach can help address the heterogeneity of GBM and inform future drug combinations.
- The study provides valuable data for the research community to further explore GBM therapeutics.